MX386342B - Móleculas de unión a her2 y cd3 biespecíficas. - Google Patents

Móleculas de unión a her2 y cd3 biespecíficas.

Info

Publication number
MX386342B
MX386342B MX2017001031A MX2017001031A MX386342B MX 386342 B MX386342 B MX 386342B MX 2017001031 A MX2017001031 A MX 2017001031A MX 2017001031 A MX2017001031 A MX 2017001031A MX 386342 B MX386342 B MX 386342B
Authority
MX
Mexico
Prior art keywords
binding molecules
her2
bispecific her2
managing
methods
Prior art date
Application number
MX2017001031A
Other languages
English (en)
Other versions
MX2017001031A (es
Inventor
Andres Lopez-Albaitero
Hong Xu
Nai- Kong V Cheung
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2017001031A publication Critical patent/MX2017001031A/es
Publication of MX386342B publication Critical patent/MX386342B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a las composiciones, los métodos y usos que incluyen moléculas de unión biespecíficas que se unen específicamente a HER2, un receptor tirosina cinasa, y a CD3, un receptor de células T, y median la citotoxicidad de las células T para manejar y tratar trastornos, como puede ser el cáncer. También se proporcionan en la presente los usos y métodos para manejar y tratar cánceres relacionados con HER2.
MX2017001031A 2014-07-25 2015-07-24 Móleculas de unión a her2 y cd3 biespecíficas. MX386342B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029342P 2014-07-25 2014-07-25
PCT/US2015/041989 WO2016014942A1 (en) 2014-07-25 2015-07-24 Bispecific her2 and cd3 binding molecules

Publications (2)

Publication Number Publication Date
MX2017001031A MX2017001031A (es) 2017-05-04
MX386342B true MX386342B (es) 2025-03-18

Family

ID=53836217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001031A MX386342B (es) 2014-07-25 2015-07-24 Móleculas de unión a her2 y cd3 biespecíficas.

Country Status (15)

Country Link
US (2) US10519248B2 (es)
EP (1) EP3172236B1 (es)
JP (1) JP6871155B2 (es)
KR (1) KR102638104B1 (es)
CN (1) CN107124884B (es)
AU (1) AU2015292374B2 (es)
BR (1) BR112017001513A2 (es)
CA (1) CA2956014C (es)
ES (1) ES2832704T3 (es)
IL (1) IL250249B (es)
MX (1) MX386342B (es)
RU (1) RU2017105849A (es)
SG (1) SG11201700506TA (es)
WO (1) WO2016014942A1 (es)
ZA (1) ZA201701341B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390883A (zh) 2013-12-17 2021-02-23 基因泰克公司 抗cd3抗体及使用方法
RU2017105849A (ru) 2014-07-25 2018-08-29 Мемориал Слоан Кеттеринг Кэнсер Сентер Биспецифические молекулы, связывающие her2 и cd3
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
CA3051484A1 (en) * 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
EA201992546A1 (ru) * 2017-04-24 2020-03-06 Мемориал Слоан Кеттеринг Кэнсер Сентер Средства на основе антител к cd33
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
AU2019234468A1 (en) * 2018-03-12 2020-10-01 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
AU2019243453B2 (en) * 2018-03-27 2024-05-02 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
JP7418346B2 (ja) * 2018-04-13 2024-01-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ４－１ＢＢＬを含むＨｅｒ２標的化抗原結合分子
WO2019241216A1 (en) * 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
JP7410143B2 (ja) * 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
AU2019387482A1 (en) * 2018-11-30 2021-06-17 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
EP3894601A4 (en) * 2018-12-11 2023-01-11 The Translational Genomics Research Institute IDENTIFICATION OF HER2 MUTATIONS IN LUNG CANCER AND METHODS OF TREATMENT
MX2021009975A (es) * 2019-02-22 2021-12-10 Memorial Sloan Kettering Cancer Center Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
AU2020270888A1 (en) * 2019-04-08 2021-11-04 Memorial Sloan Kettering Cancer Center CD19 antibodies and methods of using the same
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2020237173A1 (en) * 2019-05-23 2020-11-26 VelosBio Inc. Anti-ror1/anti-cd3 bispecific binding molecules
US20220251192A1 (en) * 2019-06-26 2022-08-11 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
US20230270857A1 (en) * 2020-07-28 2023-08-31 Memorial Sloan Kettering Cancer Center Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
WO2022081443A2 (en) * 2020-10-12 2022-04-21 Memorial Sloan Kettering Cancer Center Anti-psma antibodies and uses thereof
IL302396A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
CA3201621A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
CA3228259A1 (en) * 2021-08-04 2023-02-09 Abpro Corporation Anti-her2 antibodies and uses thereof
EP4419567A4 (en) * 2021-10-20 2025-09-17 Memorial Sloan Kettering Cancer Center MULTI-SPECIFIC ANTI-TSHR ANTIBODIES AND THEIR USES
KR102857671B1 (ko) 2021-12-29 2025-09-10 건국대학교 글로컬산학협력단 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
KR102803655B1 (ko) 2021-12-29 2025-05-08 건국대학교 글로컬산학협력단 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
AR129061A1 (es) 2022-04-13 2024-07-10 Genentech Inc Composiciones farmacéuticas de mosunetuzumab y métodos de uso
EP4658326A2 (en) * 2023-02-04 2025-12-10 Imagion Biosystems, Inc. Method to assess nodal disease using iron oxide nanoparticles in magnetic resonance imaging
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof
WO2025085781A1 (en) 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
FI2155783T4 (fi) 2007-04-03 2022-12-15 Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
WO2010099536A2 (en) 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Engineered proteins with high affinity for dota chelates
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
US9315585B2 (en) * 2010-06-19 2016-04-19 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
CN103796677B (zh) 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
PT2707031T (pt) * 2011-05-08 2019-09-05 Legochem Biosciences Inc Conjugados de proteína e agente ativo e processo para a sua preparação
EP2723380B1 (en) * 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
WO2013065869A1 (en) * 2011-11-02 2013-05-10 Ajinomoto Co.,Inc. Method for secretory production of protein
EP3786183A3 (en) * 2012-06-15 2021-06-09 Imaginab, Inc. Antigen binding constructs to cd3
CN120365432A (zh) * 2012-11-21 2025-07-25 武汉友芝友生物制药股份有限公司 双特异性抗体
HRP20220553T1 (hr) * 2013-07-25 2022-06-10 Cytomx Therapeutics Inc. Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
MY189089A (en) 2013-12-17 2022-01-25 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
RU2017105849A (ru) 2014-07-25 2018-08-29 Мемориал Слоан Кеттеринг Кэнсер Сентер Биспецифические молекулы, связывающие her2 и cd3
CN107847584B (zh) 2015-02-09 2022-01-25 纪念斯隆凯特琳癌症中心 具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CA3051484A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules

Also Published As

Publication number Publication date
CN107124884A (zh) 2017-09-01
EP3172236A1 (en) 2017-05-31
WO2016014942A1 (en) 2016-01-28
US20170210819A1 (en) 2017-07-27
IL250249B (en) 2021-04-29
MX2017001031A (es) 2017-05-04
US20200199248A1 (en) 2020-06-25
US11987642B2 (en) 2024-05-21
EP3172236B1 (en) 2020-09-30
CN107124884B (zh) 2022-11-01
CA2956014A1 (en) 2016-01-28
AU2015292374B2 (en) 2020-09-03
KR102638104B1 (ko) 2024-02-20
CA2956014C (en) 2023-10-31
US10519248B2 (en) 2019-12-31
NZ729286A (en) 2023-12-22
RU2017105849A (ru) 2018-08-29
KR20170038835A (ko) 2017-04-07
JP6871155B2 (ja) 2021-05-12
JP2017527274A (ja) 2017-09-21
AU2015292374A1 (en) 2017-03-16
ES2832704T3 (es) 2021-06-11
SG11201700506TA (en) 2017-02-27
ZA201701341B (en) 2021-05-26
BR112017001513A2 (pt) 2018-02-14
IL250249A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX386342B (es) Móleculas de unión a her2 y cd3 biespecíficas.
MX2020006668A (es) Anticuerpos para lilrb2.
PH12021552158A1 (en) Antibodies to icos
MX2015007189A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
JO3740B1 (ar) روابط pd1/ctla4
MX2015013163A (es) Complejos multiespecificos multivalente y monovalentes y sus usos.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX2018005546A (es) Anticuerpos que se unen especificamente a pd-1 y tim-3 y sus usos.
MX2017005553A (es) Terapia de combinacion para cancer.
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MA40074A (fr) Composés liant ras multivalents
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
WO2017035430A3 (en) Anti-alk antibodies and methods for use thereof
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
MX2018011244A (es) Anticuerpos monoclonales neutralizantes para il-25 y usos de estos.